In this study, we provide the first clues as to the existence of such a population of CD8+ T cells with a distinct effector program, which might be driven by underlying genetic factors, including the MS risk SNP rs6672420 in RUNX3 (rs6672420). Here, RUNX3 is linked to myeloid sarcoma.